Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

WASHINGTON, Dec 18 (Reuters) - Americans enrolled in Medicare will pay about 50% less out of pocket in 2026 for some drugs including ​Pfizer and Bristol Myers Squibb's blood thinner Eliquis and Merck ...

Three stocks that did well during the last big bear market in 2022 are AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Chevron (NYSE: CVX). Here's why they could potentially be good investments to ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is running a late-stage ...

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...

According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival's ...

Novo Nordisk's (DK:NOVO.B) next-gen medication is called CagriSema. It's a once-weekly shot that combines a long-acting amylin analogue and Wegovy. Clinical trials found that patients taking CagriSema ...

Eli Lilly’s oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Emil Kongshøj Larsen, Executive Vice President for International Operations at Novo Nordisk, talks to BT about India’s role ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...